Brady Johnson Net Worth

The estimated Net Worth of Brady Johnson is at least $575 Thousand dollars as of 21 March 2022. Mr Johnson owns over 654 units of Cidara Therapeutics Inc stock worth over $573,633 and over the last 6 years he sold CDTX stock worth over $1,721.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Johnson CDTX stock SEC Form 4 insiders trading

Mr has made over 3 trades of the Cidara Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 654 units of CDTX stock worth $530 on 21 March 2022.

The largest trade he's ever made was selling 945 units of Cidara Therapeutics Inc stock on 11 March 2022 worth over $671. On average, Mr trades about 288 units every 12 days since 2018. As of 21 March 2022 he still owns at least 49,366 units of Cidara Therapeutics Inc stock.

You can see the complete history of Mr Johnson stock trades at the bottom of the page.

Mr. Brady Johnson biography

Brady Johnson is the Principal Accounting Officer, Controller & VP of Fin. at Cidara Therapeutics Inc.

What's Mr Johnson's mailing address?

Brady's mailing address filed with the SEC is 6310 Nancy Ridge Dr, San Diego, CA 92121, USA.

Insiders trading at Cidara Therapeutics Inc

Over the last 15 years, insiders at Cidara Therapeutics Inc have traded over $256,071 worth of Cidara Therapeutics Inc stock and bought 1,216,676 units worth $9,796,257 . The most active insiders traders include Capital Management, L.P.Ra ..., Target N Vbb Biotech Ag Bio..., and Steve Elms. On average, Cidara Therapeutics Inc executives and independent directors trade stock every 52 days with the average trade being worth of $282,598. The most recent stock trade was executed by Jeffrey Stein on 7 June 2024, trading 8,000 units of CDTX stock currently worth $105,680.

What does Cidara Therapeutics Inc do?

cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.

Complete history of Mr Johnson stock trades at Cidara Therapeutics Inc

Cidara Therapeutics Inc executives and stock owners

Cidara Therapeutics Inc executives and other stock owners filed with the SEC include:

• Jeffrey Stein,
  President, Chief Executive Officer, Director
• Dr. Jeffrey L. Stein Ph.D.,
  Pres, CEO & Exec. Director
• Neil Abdollahian,
  Chief Business Officer
• Taylor Sandison,
  Chief Medical Officer
• Paul Daruwala,
  Chief Operating Officer
• Dr. Taylor Sandison,
  Chief Medical Officer
• Daniel Burgess,
  Independent Chairman of the Board
• Theodore Schroeder,
  Independent Director
• Chrysa Mineo,
  Independent Director
• Timothy Franson,
  Independent Director
• David Gollaher,
  Independent Director
• Robert Uhl,
  IR Contact Officer
• Jessica Oien,
  General Counsel, Secretary
• James Levine,
  Chief Financial Officer
• Dr. Kenneth F. Bartizal Ph.D.,
  Chief Devel. Officer
• Allison Lewis CCP, SPHR,
  VP of HR
• Shane M. Ward,
  Chief Legal Officer & Corp. Sec.
• Christopher A. Kurtz,
  Exec. VP of Technical Operations
• Brady Johnson,
  Principal Accounting Officer, Controller & VP of Fin.
• Paul Daruwala,
  COO & Chief Commercial Officer
• Dr. Preetam Shah M.B.A., Ph.D.,
  CFO & Chief Bus. Officer
• Dr. Kevin M. Forrest Ph.D.,
  Founder and Chief Strategy Officer
• Robert J Perez,
  Director
• Scott M Rocklage,
  Director
• Ken Bartizal,
  Chief Development Officer
• Matthew Onaitis,
  Gnrl Counsel, CFO & Secretary
• Marc Wilson,
  Chief Accounting Officer
• Dirk Thye,
  Chief Medical Officer
• Kevin Forrest,
  COO & CFO
• Laura Tadvalkar,
  Director
• Preetam Shah,
  CFO & CBO
• Target N Vbb Biotech Ag Bio...,
  
• Patrick J Heron,
  Director
• Nina S Kjellson,
  Director
• Steve Elms,
  Director
• Bonnie L Bassler,
  Director
• Carin Canale Theakston,
  Director
• Leslie Tari,
  CHIEF SCIENTIFIC OFFICER
• Brady Johnson,
  Vice President, Finance
• Shane Ward,
  COO & CLO
• Ryan Spencer,
  Director
• James Merson,
  Director
• Capital Management, L.P.Ra ...,